152 related articles for article (PubMed ID: 35433321)
1. Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness.
Drosos P; Johnsen E; Bartz-Johannessen CA; Larsen TK; Reitan SK; Rettenbacher M; Kroken RA
World J Psychiatry; 2022 Mar; 12(3):521-532. PubMed ID: 35433321
[TBL] [Abstract][Full Text] [Related]
2. Amisulpride, aripiprazole, and olanzapine in patients with schizophrenia-spectrum disorders (BeSt InTro): a pragmatic, rater-blind, semi-randomised trial.
Johnsen E; Kroken RA; Løberg EM; Rettenbacher M; Joa I; Larsen TK; Reitan SK; Walla B; Alisauskiene R; Anda LG; Bartz-Johannessen C; Berle JØ; Bjarke J; Fathian F; Hugdahl K; Kjelby E; Sinkeviciute I; Skrede S; Stabell L; Steen VM; Fleischhacker WW
Lancet Psychiatry; 2020 Nov; 7(11):945-954. PubMed ID: 33069317
[TBL] [Abstract][Full Text] [Related]
3. Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.
Mørkved N; Johnsen E; Kroken RA; Winje D; Larsen TK; Thimm JC; Rettenbacher MA; Johannesen CAB; Løberg EM
Schizophr Res; 2022 Aug; 246():49-59. PubMed ID: 35709647
[TBL] [Abstract][Full Text] [Related]
4. Does drug use affect the efficacy of amisulpride, aripiprazole and olanzapine in patients with schizophrenia spectrum disorders? Results from a pragmatic, randomised study.
Alisauskiene R; Johnsen E; Gjestad R; Kroken RA; Kjelby E; Sinkeviciute I; Fathian F; Joa I; Reitan SK; Rettenbacher M; Løberg EM
Gen Hosp Psychiatry; 2023; 83():185-193. PubMed ID: 37269769
[TBL] [Abstract][Full Text] [Related]
5. Differential Effectiveness of Atypical Antipsychotics on Hallucinations: A Pragmatic Randomized Controlled Trial.
Sinkeviciute I; Hugdahl K; Bartz-Johannessen C; Kroken RA; Løberg EM; Kjelby E; Rettenbacher MA; Joa I; Reitan SK; Alisauskiene R; Fathian F; Johnsen E
J Clin Psychopharmacol; 2021 Jul-Aug 01; 41(4):389-396. PubMed ID: 33938520
[TBL] [Abstract][Full Text] [Related]
6. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
[TBL] [Abstract][Full Text] [Related]
7. Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders: A Secondary Outcome Analysis of a Pragmatic, Randomized Trial (BeSt InTro).
Kjelby E; Gjestad R; Fathian F; Sinkeviciute I; Alisauskiene R; Anda L; Løberg EM; Reitan SK; Joa I; Larsen TK; Rettenbacher M; Berle JØ; Fasmer OB; Kroken RA; Johnsen E
J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):246-258. PubMed ID: 37083542
[TBL] [Abstract][Full Text] [Related]
8. Clinical insight among persons with schizophrenia spectrum disorders treated with amisulpride, aripiprazole or olanzapine: a semi-randomised trial.
Stabell LA; Johnsen E; Kroken RA; Løberg EM; Blindheim A; Joa I; Reitan SK; Rettenbacher M; Munk-Jørgensen P; Gjestad R
BMC Psychiatry; 2023 Jun; 23(1):482. PubMed ID: 37386462
[TBL] [Abstract][Full Text] [Related]
9. Cognitive change and antipsychotic medications: Results from a pragmatic rater-blind RCT.
Anda L; Johnsen E; Kroken RA; Joa I; Rettenbacher M; Løberg EM
Schizophr Res Cogn; 2021 Dec; 26():100204. PubMed ID: 34258237
[TBL] [Abstract][Full Text] [Related]
10. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
Yıldız M; Osman E
Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
[TBL] [Abstract][Full Text] [Related]
12. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole versus other atypical antipsychotics for schizophrenia.
Khanna P; Komossa K; Rummel-Kluge C; Hunger H; Schwarz S; El-Sayeh HG; Leucht S
Cochrane Database Syst Rev; 2013 Feb; (2):CD006569. PubMed ID: 23450570
[TBL] [Abstract][Full Text] [Related]
14. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial.
Pagsberg AK; Jeppesen P; Klauber DG; Jensen KG; Rudå D; Stentebjerg-Olesen M; Jantzen P; Rasmussen S; Saldeen EA; Lauritsen MG; Bilenberg N; Stenstrøm AD; Nyvang L; Madsen S; Werge TM; Lange T; Gluud C; Skoog M; Winkel P; Jepsen JRM; Fagerlund B; Correll CU; Fink-Jensen A
Lancet Psychiatry; 2017 Aug; 4(8):605-618. PubMed ID: 28599949
[TBL] [Abstract][Full Text] [Related]
15. Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trial.
Levine SZ; Rabinowitz J; Faries D; Lawson AH; Ascher-Svanum H
Schizophr Res; 2012 May; 137(1-3):141-6. PubMed ID: 22316567
[TBL] [Abstract][Full Text] [Related]
16. Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial.
Schmidt-Kraepelin C; Feyerabend S; Engelke C; Riesbeck M; Meisenzahl-Lechner E; Verde PE; Correll CU; Kluge M; Makiol C; Neff A; Lange C; Englisch S; Zink M; Langguth B; Poeppl TB; Reske D; Gouzoulis-Mayfrank E; Gründer G; Hasan A; Brockhaus-Dumke A; Jäger M; Baumgärtner J; Leucht S; Cordes J;
Lancet Psychiatry; 2022 Apr; 9(4):291-306. PubMed ID: 35276079
[TBL] [Abstract][Full Text] [Related]
17. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal trajectory analysis of antipsychotic response in patients with schizophrenia: 6-week, randomised, open-label, multicentre clinical trial.
Dai M; Wu Y; Tang Y; Yue W; Yan H; Zhang Y; Tan L; Deng W; Chen Q; Yang G; Lu T; Wang L; Yang F; Zhang F; Yang J; Li K; Lv L; Tan Q; Zhang H; Ma X; Li L; Wang C; Ma X; Zhang D; Yu H; Zhao L; Ren H; Wang Y; Hu X; Zhang G; Du X; Wang Q; Li T;
BJPsych Open; 2020 Oct; 6(6):e126. PubMed ID: 33090091
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM
Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187
[TBL] [Abstract][Full Text] [Related]
20. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
